Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study ; volume:9 ; number:1 ; day:4 ; month:7 ; year:2023 ; pages:1-10 ; date:12.2023
Pilot and feasibility studies ; 9, Heft 1 (4.7.2023), 1-10, 12.2023
- Creator
-
Hard, Bernadette
DeSilva, Mohan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40814-023-01348-5
- URN
-
urn:nbn:de:101:1-2023093011263550421500
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hard, Bernadette
- DeSilva, Mohan
- SpringerLink (Online service)
Other Objects (12)
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Physicians’ satisfaction with providing buprenorphine treatment
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Physicians’ satisfaction with providing buprenorphine treatment
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study